The potential of amifostine: From cytoprotectant to therapeutic agent

Keyphrases

• Therapeutic Agents 100%
• Amifostine 100%
• Cytoprotectant 100%
• Cisplatin 20%
• Chemotherapy 12%
• Cyclophosphamide 12%
• Radiotherapy 8%
• Myelodysplastic Syndrome 8%
• Neurotoxicity 8%
• Hematologic 8%
• Prodrug 8%
• Carboplatin 8%
• Alkaline Phosphatase 8%
• Partial Response 8%
• Scavenger 8%
• Vinblastine 8%
• Thiophosphate 8%
• Cytoprotective Agents 8%
• Free Thiols 8%
• Clinical Trials 4%
• Amino 4%
• Clinical Application 4%
• Peripheral Nerve 4%
• Antitumor Activity 4%
• Growth Factors 4%
• Radiation Dose 4%
• Hypotension 4%
• Hematopoiesis 4%
• Phase I Study 4%
• Thrombocytopenia 4%
• Doxorubicin 4%
• Neoplasms 4%
• Ionizing Radiation 4%
• Peripheral Neuropathy 4%
• Phase II Study 4%
• Tolerability 4%
• Cytotoxicity 4%
• Lymphoma 4%
• Tumor Tissue 4%
• Bleomycin 4%
• Cytotoxic Therapy 4%
• Cardiotoxicity 4%
• Clinical Protocols 4%
• Solid Tumors 4%
• Dosing Regimen 4%
• Lethal Dose 4%
• Nephrotoxicity 4%
• Salivary Gland 4%
• Mucosa 4%
• Active Metabolite 4%
• Metastatic Tumor 4%
• Elderly Patients 4%
• Cytotoxic Drugs 4%
• Renal Toxicity 4%
• Free Radicals 4%
• First Observation 4%
• Pulmonary Toxicity 4%
• Antitumor Effect 4%
• MEDLINE 4%
• Oxygen Radicals 4%
• Multiple Phases 4%
• Reactive Compounds 4%
• Cytopenia 4%
• High-dose Chemotherapy 4%
• Neutropenia 4%
• Radioprotection 4%
• Nitrogen mustard 4%
• Tumor-bearing Animals 4%
• Supportive Treatment 4%
• Animal Species 4%
• Clinical Complications 4%
• Cisplatin-induced 4%
• Chemotherapy Toxicity 4%
• Mucositis 4%
• Hematotoxicity 4%
• Multiple Dose 4%
• Cytotoxic Agents 4%
• 5-fluorouracil (5-FU) 4%
• Myelodysplasia 4%
• Alkylating Drugs 4%
• Alkylating Agents 4%
• Melphalan 4%
• Cytoprotection 4%
• Mitomycin C 4%
• Skin Glands 4%
• Advanced Solid Tumors 4%
• Appropriate Dose 4%
• Platinum Agents 4%
• WR-2721 4%
• Myeloprotective 4%
• Renal Nerves 4%
• Organ Protection 4%
• Reactive Metabolites 4%
• Aminopropyl 4%
• Single-dose Treatment 4%
• Dihydrogen Phosphate 4%
• Preclinical Animal Studies 4%
• Ethanethiol 4%
• Low-risk MDS 4%
• Cisplatin Nephrotoxicity 4%
• Early Application 4%
• Declassification 4%
• Nerve Protection 4%
• Cytoprotective Drugs 4%
• Nuclear Warfare 4%
• Fotemustine 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Cytoprotective Agent 100%
• Amifostine 100%
• Cisplatin 26%
• Chemotherapy 15%
• Neoplasm 15%
• Myelodysplastic Syndrome 15%
• Cyclophosphamide 11%
• Nephrotoxicity 7%
• Thiophosphate 7%
• Prodrug 7%
• Solid Malignant Neoplasm 7%
• Vinblastine 7%
• Cytotoxic Agent 7%
• Carboplatin 7%
• Alkaline Phosphatase 7%
• Thiol 7%
• Doxorubicin 3%
• Tolerability 3%
• Nitrogen Mustard 3%
• Neurotoxicity 3%
• Antitumor Activity 3%
• Mitomycin 3%
• Cytotoxic Chemotherapy 3%
• High Dose Chemotherapy 3%
• Cardiotoxicity 3%
• Clinical Trial 3%
• Growth Factor 3%
• Hypotension 3%
• Ionizing Radiation 3%
• Bleomycin 3%
• Side Effect 3%
• Active Metabolite 3%
• Free Radical 3%
• Neuropathy 3%
• Lung Toxicity 3%
• Mucosa Inflammation 3%
• Oxygen Radical 3%
• Melphalan 3%
• Fotemustine 3%
• Radioprotective Agent 3%
• Thrombocytopenia 3%
• Cytopenia 3%
• Neutropenia 3%
• Cytoprotection 3%
• Cytotoxicity 3%